Analysts expect Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) to announce earnings of ($0.69) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Diffusion Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.90) and the highest estimate coming in at ($0.48). Diffusion Pharmaceuticals posted earnings of ($0.75) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 8%. The business is scheduled to report its next earnings results on Monday, August 12th.
According to Zacks, analysts expect that Diffusion Pharmaceuticals will report full year earnings of ($2.27) per share for the current financial year, with EPS estimates ranging from ($2.28) to ($2.25). For the next financial year, analysts forecast that the firm will report earnings of ($1.48) per share, with EPS estimates ranging from ($1.57) to ($1.39). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Diffusion Pharmaceuticals.
Diffusion Pharmaceuticals (NASDAQ:DFFN) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.09.
Several equities research analysts have issued reports on DFFN shares. HC Wainwright lifted their price target on Diffusion Pharmaceuticals to $10.00 and gave the stock a “buy” rating in a research note on Wednesday, March 20th. ValuEngine lowered Diffusion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, February 2nd.
DFFN stock traded down $0.26 during mid-day trading on Thursday, hitting $4.40. 46,909 shares of the stock were exchanged, compared to its average volume of 861,563. The company has a quick ratio of 5.35, a current ratio of 5.35 and a debt-to-equity ratio of 0.02. Diffusion Pharmaceuticals has a 12 month low of $1.83 and a 12 month high of $11.00.
An institutional investor recently bought a new position in Diffusion Pharmaceuticals stock. Two Sigma Investments LP acquired a new position in Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 32,176 shares of the company’s stock, valued at approximately $64,000. Two Sigma Investments LP owned 0.95% of Diffusion Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 5.69% of the company’s stock.
Diffusion Pharmaceuticals Company Profile
Diffusion Pharmaceuticals Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke.
Featured Article: What is the NASDAQ?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.